Stroke
Conference Coverage
Real-world data support safety of newer LAA device
More than 18 months after approval, the Watchman FLX left atrial appendage closure device is performing well at 45 days in real-world use.
From the Journals
Silver lining emerges for embolic protection in post-TAVR stroke
A database study found that embolic protection during transcatheter aortic valve replacement may improve outcomes, although not the occurrence, of...
Conference Coverage
Robotic transcranial Doppler improves PFO detection after stroke
It’s hoped that use of the robotic device will increase the number of shunts identified.
Conference Coverage
Liquid embolism of AVM tied to high cure rate
“Endovascular treatment using Onyx is able to achieve, on its own, a very efficient cure rate with a low morbidity and mortality rate,”
Conference Coverage
Tenecteplase for stroke thrombolysis up to 24 hours?
“These results are the first to be reported with tenecteplase in the extended time window.”
Conference Coverage
Tirofiban does not improve outcomes of endovascular treatment in stroke
Median Modified Rankin Scale (mRS) score at 90 days was 3 in both patients who received tirofiban and those who received placebo.
Conference Coverage
DOACs comparable to warfarin in CVT
“This real-world data supports use of direct oral anticoagulant drugs as a reasonable alternative to warfarin in patients with cerebral venous...
Conference Coverage
Stroke risk is highest right after COVID infection
The study highlights the impact COVID-19 has on the cardiovascular system.
From the Journals
AHA statement reviews marijuana’s effects on brain health
“Social media tends to overemphasize the beneficial effects of marijuana. However, its ultimate effect on brain health is still to be established...
Conference Coverage
Can periodontal treatment reduce cardiovascular events in stroke patients?
“Even standard periodontal care – a dental cleaning every 3 months – was beneficial.”
Conference Coverage
Tenecteplase for stroke linked to reduced ICH risk
The rate of symptomatic hemorrhage after getting a thrombolytic is half that with tenecteplase than with alteplase.